Panelists: Dr. Krystelle Godbout, Dr. Richard Leigh, Dr. Diane Lougheed, Harold Kim, Dr. Param Nair, Dr. Padmaja Subbarao
Moderator: Dr. Clare Ramsey
A panel discussion on key questions related to use of a precision medicine approach to manage patients with severe asthma.
Learning objectives
At the end of the session, attendees will be able to:
- Choose the right treatment for the right patient when it comes to biologics for severe asthma (including discussion of different mechanisms of action, and how to determine responsiveness);
- Identify key patient characteristics to assess and considerations for those patients with comorbid conditions;
- Discuss if eosinophils are a valuable biomarker for responsiveness to biologics (consider sputum vs blood); and
- Identify and discuss merit of other potential biomarkers for use of biologics in severe asthma (e.g. FeNO)
This session is co-developed by the Canadian Thoracic Society and GSK and is planned to achieve scientific integrity, objectivity and balance.
